Background: Patients with coronary heart disease (CHD) are advised to reduce their intake of foods rich in saturated fatty acids (SFA) and substitute foods rich in complex carbohydrates, polyunsaturated fatty acids (PUFA) and monounsaturated fatty acids (MUFA).
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Methods: In the LIPID Study, 9014 patients were randomised to Pravastatin 40mg/day or placebo and followed up for a mean of 6 years. Dietary advice was given to all patients to reduce fat intake to less than 30% of energy intake, with equal amounts of SFA, PUFA and MUFA. Mortality and CHD event rates were higher in New Zealand patients. Baseline characteristics of patients were similar in both countries. However in New Zealand, median low-density lipoprotein cholesterol was higher (3.95 vs 3.81 mmol/L, P = 0.0002) and high-density lipoprotein cholesterol was lower (0.88 vs 0.94 mmol/L, P < 0.001). A validated questionnaire was used to assess adherence to the diet in three different years (1991, 1992, 1995) in 1077, 951 and 849 patients respectively.
Results: Total energy intake was higher in New Zealand in 1991, 1992 and 1995 and declined in both countries. Total fat and SFA and MUFA in absolute amounts and as a percentage of energy intake were higher in New Zealand. PUFA, as a percentage of energy intake, were similar in both countries.
Conclusions: The higher intake of fat in New Zealand patients may partly explain the higher CHD event rates observed in the LIPID Study. 
